OVID THERAPEUTICS INC.

Ovid Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights

08 Nov 2022 07:00:02 By Nasdaq GlobeNewswire

Ovid Therapeutics to Present at the Ladenburg Thalmann 2022 Healthcare Conference

27 Sep 2022 07:00:00 By Nasdaq GlobeNewswire

Ovid Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

07 Sep 2022 07:00:02 By Nasdaq GlobeNewswire

Ovid Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights

09 Aug 2022 07:00:02 By Nasdaq GlobeNewswire

Ovid Therapeutics Presents Preclinical Data on OV329 at the Epilepsy Foundation Pipeline Conference

06 Jun 2022 07:00:02 By Nasdaq GlobeNewswire

Ovid Therapeutics Reports First Quarter 2022 Financial Results and Corporate Highlights

10 May 2022 07:00:04 By Nasdaq GlobeNewswire

Ovid Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

08 Apr 2022 07:00:00 By Nasdaq GlobeNewswire

Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2021 Financial Results

15 Mar 2022 07:00:03 By Nasdaq GlobeNewswire

Ovid Therapeutics to Participate at the Cowen 42nd Annual Health Care Conference

04 Mar 2022 07:00:00 By Nasdaq GlobeNewswire

Healx and Ovid Therapeutics to Enter Strategic Partnership

08 Feb 2022 07:00:03 By Nasdaq GlobeNewswire

Ovid Therapeutics Expands Epilepsy Franchise with Novel KCC2 Activators

03 Jan 2022 05:30:00 By Nasdaq GlobeNewswire

Ovid Therapeutics Reports Third Quarter 2021 Business Update, Corporate Highlights and Financial Results

10 Nov 2021 07:30:00 By Nasdaq GlobeNewswire

Ovid Therapeutics Appoints Dr. Kevin Fitzgerald to Board of Directors

07 Oct 2021 07:30:00 By Nasdaq GlobeNewswire

Ovid Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

07 Sep 2021 07:00:01 By Nasdaq GlobeNewswire

Ovid Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Highlights

16 Aug 2021 07:00:02 By Nasdaq GlobeNewswire

Ovid Therapeutics Strengthens Board & Leadership Team to Focus Efforts on Expanding Its Neurosciences Capabilities

08 Jul 2021 15:30:00 By Nasdaq GlobeNewswire

Ovid Therapeutics to Present at the Ladenburg Thalmann 2021 Healthcare Conference

07 Jul 2021 07:00:01 By Nasdaq GlobeNewswire

Ovid Therapeutics Appoints Jeff Rona as Chief Business and Financial Officer

04 Jun 2021 07:00:00 By Nasdaq GlobeNewswire

Ovid Therapeutics Appoints Dr. Joy A. Cavagnaro and Dr. Bruce A. Sullenger to its Scientific Advisory Board

26 May 2021 07:00:02 By Nasdaq GlobeNewswire

Ovid Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update

13 May 2021 15:05:01 By Nasdaq GlobeNewswire